SCHEMBL5378366

SCHEMBL5378366

CCCN(CCO)S(=O)(=O)CCC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@@H](O)CNCc1cccc(CC)c1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.65
CTSD P07339 5/20 0.65
CTSB P07858 14/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378362 1.00 BACE1 (0.65) BACE1CTSDCTSB
SCHEMBL5349244 0.97 BACE1 (0.69) BACE1CTSDCTSB
SCHEMBL5349238 0.97 BACE1 (0.69) BACE1CTSDCTSB
SCHEMBL6701136 0.90 BACE1 (0.65) BACE1CTSDCTSB
SCHEMBL6701131 0.90 BACE1 (0.65) BACE1CTSDCTSB
SCHEMBL3349575 0.89 BACE1 (0.67) BACE1CTSDCTSB
SCHEMBL3349578 0.89 BACE1 (0.67) BACE1CTSDCTSB
SCHEMBL3356725 0.88 BACE1 (0.66) BACE1CTSDCTSB
SCHEMBL3356732 0.88 BACE1 (0.66) BACE1CTSDCTSB
SCHEMBL3349137 0.88 BACE1 (0.66) BACE1CTSDCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP claimed
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives PHARMACIA & UPJOHN COMPANY 2004-09-02 US claimed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171881-A1 N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives BACE1, BACE2, PSEN1 BACE1 1/4885CTSD 249/4885CTSB 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.